Acrivon Therapeutics (ACRV) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 17, 2026, to be held virtually for stockholders of record as of April 23, 2026.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request by June 5, 2026.

Voting matters and shareholder proposals

• Election of two Class I directors: Michael Tomsicek, M.B.A., and Charles Baum, M.D., Ph.D.

• Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Consideration of other business that may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting FOR all director nominees and FOR the ratification of the auditor.